Neuronetics Ownership
| STIM Stock | USD 4.49 0.04 0.90% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 32 M | Current Value 61 M | Avarage Shares Outstanding 25.3 M | Quarterly Volatility 9.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Neuronetics | Build AI portfolio with Neuronetics Stock |
Neuronetics Stock Ownership Analysis
About 63.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.32. Neuronetics had not issued any dividends in recent years. Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. To find out more about Neuronetics contact Keith Sullivan at 610 640 4202 or learn more at https://neurostar.com.Neuronetics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuronetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuronetics backward and forwards among themselves. Neuronetics' institutional investor refers to the entity that pools money to purchase Neuronetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2025-03-31 | 415.9 K | Ghisallo Capital Management Llc | 2025-03-31 | 400 K | Boothbay Fund Management, Llc | 2025-03-31 | 347.2 K | Centerbook Partners Lp | 2025-03-31 | 326.1 K | Geode Capital Management, Llc | 2025-03-31 | 322.8 K | Cubist Systematic Strategies, Llc | 2025-03-31 | 286.6 K | Bank Of America Corp | 2025-03-31 | 253.6 K | Awm Investment Company Inc | 2025-03-31 | 245.9 K | Walleye Trading Advisors, Llc | 2025-03-31 | 242.4 K | Vanguard Group Inc | 2025-03-31 | 2.3 M | Balyasny Asset Management Llc | 2025-03-31 | 1.4 M |
Neuronetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuronetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuronetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuronetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuronetics Outstanding Bonds
Neuronetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuronetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuronetics bonds can be classified according to their maturity, which is the date when Neuronetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth 0.836 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.